Payment overview · 2025
General Payments
$1,791.69
98 reported records · 26 companies
Healthcare provider profile · identity verified
Augustine V Joseph, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · ORLANDO, FL · NPI 1750360459
Verified facts
What the public records show
CMS Open Payments records show Augustine V Joseph, MD received $1,791.69 in general payments during 2025 across 98 reported records.
ABBVIE INC. accounted for 10.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Fycompa, Gocovri, Nuplazid, Nurtec Odt, Ponvory, Qulipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ubrelvy by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Nuplazid by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TECFIDERA as an associated drug or biological on 28 records involving 22 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tecfidera by this doctor in 2024.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Fycompa by this doctor in 2024.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Apokyn as an associated drug or biological on 1207 records involving 338 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Apokyn by this doctor in 2024.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gocovri as an associated drug or biological on 3202 records involving 1029 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Gocovri by this doctor in 2024.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xadago as an associated drug or biological on 139 records involving 79 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xadago by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Xcopri by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Austedo by this doctor in 2024.
Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PONVORY as an associated drug or biological on 6985 records involving 2313 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ponvory by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $194.75 | 10.9% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $161.54 | 9.0% | 13 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $152.90 | 8.5% | 7 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $141.70 | 7.9% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $136.74 | 7.6% | 6 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$96.90 | 5.4% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $96.29 | 5.4% | 4 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $87.83 | 4.9% | 4 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $83.62 | 4.7% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $82.44 | 4.6% | 3 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $67.60 | 3.8% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $67.22 | 3.8% | 4 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $58.57 | 3.3% | 3 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $51.02 | 2.9% | 2 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $43.35 | 2.4% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $33.25 | 1.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $33.09 | 1.9% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.39 | 1.7% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $30.20 | 1.7% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $29.88 | 1.7% | 2 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $23.90 | 1.3% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$23.23 | 1.3% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $17.28 | 1.0% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $17.24 | 1.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.62 | 0.9% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $15.14 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,763.06 | 97 |
| Education | $28.63 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $141.70 | 10 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $140.05 | 9 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $136.74 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $118.30 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $105.98 | 11 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $105.98 | 11 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $96.29 | 4 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $89.15 | 5 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $82.44 | 3 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $76.45 | 5 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $67.60 | 4 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $67.22 | 4 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $63.75 | 2 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $58.73 | 3 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $58.57 | 3 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $55.56 | 2 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $55.56 | 2 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $55.09 | 3 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $51.02 | 2 | 2025 |
Source payment records
|
|||||
| AVONEX Normalized: avonex |
Biological | Biogen, Inc. | $44.21 | 2 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $44.21 | 2 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $43.35 | 2 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $33.25 | 2 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $33.09 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $30.39 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $29.88 | 2 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $23.90 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $23.23 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $15.62 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $15.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 47 | exact normalized | Medicare Part D |
| FYCOMPA fycompa |
2025 | Fycompa | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Gocovri gocovri |
2025 | Gocovri | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PONVORY ponvory |
2025 | Ponvory | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
47 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TECFIDERA open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 22 recipient NPIs · example record 1208304358 |
Tecfidera · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Apokyn open payments reported associated product |
CMS Open Payments — General Payments 1207 supporting records · 338 recipient NPIs · example record 1241843684 |
Apokyn · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Gocovri open payments reported associated product |
CMS Open Payments — General Payments 3202 supporting records · 1029 recipient NPIs · example record 1241843637 |
Gocovri · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Xadago open payments reported associated product |
CMS Open Payments — General Payments 139 supporting records · 79 recipient NPIs · example record 1241843808 |
Xadago · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | PONVORY open payments reported associated product |
CMS Open Payments — General Payments 6985 supporting records · 2313 recipient NPIs · example record 1232940557 |
Ponvory · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 381 | 135 |
| Levetiracetam | Levetiracetam | 290 | 71 |
| Memantine Hcl | Memantine Hcl | 260 | 95 |
| Gabapentin | Gabapentin | 204 | 65 |
| Topiramate | Topiramate | 144 | 52 |
| Primidone | Primidone | 140 | 40 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 118 | 31 |
| Amitriptyline Hcl | Amitriptyline Hcl | 82 | 23 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 81 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 76 | 23 |
| Propranolol Hcl Er | Propranolol Hcl | 73 | 25 |
| Sumatriptan Succinate | Sumatriptan Succinate | 72 | 22 |
| Lamotrigine | Lamotrigine | 70 | 15 |
| Xcopri | Cenobamate | 70 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 60 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 59 | 16 |
| Lorazepam | Lorazepam | 58 | 21 |
| Clonazepam | Clonazepam | 57 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 50 | 18 |
| Phenobarbital | Phenobarbital | 50 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 49 | suppressed |
| Baclofen | Baclofen | 48 | 15 |
| Botox | Onabotulinumtoxina | 47 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 47 | suppressed |
| Pregabalin | Pregabalin | 46 | 13 |
| Nurtec Odt | Rimegepant Sulfate | 45 | suppressed |
| Carbamazepine | Carbamazepine | 43 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 42 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 39 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | 15 |
| Oxcarbazepine | Oxcarbazepine | 37 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 13 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 35 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | suppressed |
| Lacosamide | Lacosamide | 31 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Fycompa | Perampanel | 30 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 15 |
| Emgality Pen | Galcanezumab-Gnlm | 26 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Modafinil | Modafinil | 24 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 24 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Zonisamide | Zonisamide | 20 | suppressed |
| Dalfampridine Er | Dalfampridine | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Apokyn | Apomorphine Hcl | 17 | suppressed |
| Rivastigmine | Rivastigmine | 17 | suppressed |
| Entacapone | Entacapone | 16 | suppressed |
| Qulipta | Atogepant | 16 | suppressed |
| Depakote | Divalproex Sodium | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Dexamethasone | Dexamethasone | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Ponvory | Ponesimod | 13 | suppressed |
| Rytary | Carbidopa/Levodopa | 13 | suppressed |
| Xadago | Safinamide Mesylate | 13 | suppressed |
| Zolmitriptan | Zolmitriptan | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Gocovri | Amantadine Hcl | 12 | suppressed |
| Tecfidera | Dimethyl Fumarate | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Austedo | Deutetrabenazine | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,791.69 · 98 records | ABBVIE INC. | ACTHAR, AUSTEDO XR, AVONEX, BOTOX, BRIUMVI, Briviact, FYCOMPA, Gocovri, INBRIJA, INGREZZA, KESIMPTA, KISUNLA, LEQEMBI, NUPLAZID, NURTEC ODT, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ocrevus Zunovo, PANZYGA, PONVORY, PURIFIED CORTROPHIN GEL, QULIPTA, Radicava, Rystiggo, TYSABRI, UBRELVY, UPLIZNA, VALTOCO, VUMERITY, VYEPTI, VYVGART HYTRULO, WAKIX, Xeomin, ZAVZPRET | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error